We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03322813
Recruitment Status : Suspended (Study temporarily suspended until priorities are reassessed)
First Posted : October 26, 2017
Last Update Posted : August 3, 2022
Information provided by (Responsible Party):

Brief Summary:
This study is designed to assess the safety and feasibility of using the ExAblate, Type 2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma. The ExAblate Model 4000 Type-2 is intended for use as a tool to disrupt the BBB.

Condition or disease Intervention/treatment Phase
Glioma Device: ExAblate 4000 - Type 2 Not Applicable

Detailed Description:
This study is a prospective, single-arm, non-randomized, open-label feasibility study to evaluate the safety of focal BBBD using the ExAblate® 4000 Type 2 system. Up to 15 subjects with suspected infiltrating glioma who are scheduled to undergo brain tumor resection may be recruited for the study. Only patients that have a non-enhancing tumor components in a non-eloquent region of the planned standard-of-care resection volume will be eligible. Up to 4 centers may participate in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Patients With Suspected Infiltrating Glioma in the Setting of Planned Surgical Interventions
Estimated Study Start Date : October 2023
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ExAblate 4000 - Type 2
ExAblate BBBD
Device: ExAblate 4000 - Type 2
Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
Other Name: ExAblate BBBD

Primary Outcome Measures :
  1. Device and procedure related adverse events [ Time Frame: At the time of the ExAblate MRgFUS procedure ]
    The number and severity of device and BBBD procedure related adverse events will be evaluated.

Secondary Outcome Measures :
  1. Feasibility of BBB disruption [ Time Frame: At the time of the ExAblate MRgFUS procedure and 24 hours post-procedure ]
    The extent and reversibility of BBB opening will be determined by the degree of contrast enhancement seen on post-procedure MRI with contrast agent

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or Female between 21-85 years of age
  2. Able and willing to give informed consent
  3. Subjects with suspected infiltrating glioma on pre-operative brain imaging scans including non-enhancing MRI tumor components in non-eloquent regions that are within the planned surgical resection volume
  4. Surgical area targeted for ExAblate treatment (i.e. prescribed Region of Treatment) ≤30 cm3; planned surgical resection volume may exceed the targeted treatment volume
  5. Karnofsky Performance Score 70-100
  6. Able to communicate sensations during the ExAblate® BBBD procedure

Exclusion Criteria:

  1. MRI or clinical findings of:

    • Active or chronic infection(s) or inflammatory processes
    • Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macrohemorrhages
    • Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis
    • Evidence of tumor-related calcification, cyst, or hemorrhage
    • Midline shift of >10mm or evidence of subfalcine, uncal, or tonsillar herniation on pre-operative imaging
  2. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp
  3. Clips, shunts, or any metallic implanted objects in the skull or the brain or the presence of unknown MR unsafe devices anywhere within the body
  4. Significant cardiac disease or unstable hemodynamic status
  5. Uncontrolled hypertension (systolic > 150 and diastolic BP > 100 on medication)
  6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk of hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
  7. History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage
  8. Abnormal coagulation profile (Platelets < 100,000), PT (>14) or PTT (>36), and INR > 1.3
  9. Lacunar lesions or evidence of increased risk of bleeding
  10. Known cerebral or systemic vasculopathy
  11. Significant depression and at potential risk of suicide
  12. Known sensitivity/allergy to gadolinium, or other intravascular contrast agents
  13. Active seizures despite medication treatment (defined as >1 seizure per month) which could be worsened by disruption of the blood brain barrier
  14. Evidence of worsening neurological function
  15. Dexamethasone dose ≥ 24mg daily or equivalent steroid dose
  16. History of drug or alcohol disorder which have a higher risk for seizures, infection and/or poor executive functioning
  17. Positive HIV status, which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis
  18. Potential blood-borne infections which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess
  19. Any contraindications to MRI scanning, including:

    • Large subjects not fitting comfortably into the scanner
    • Difficulty lying supine and still for up to 3 hours in the MRI unit or claustrophobia
  20. Untreated, uncontrolled sleep apnea
  21. Impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2
  22. Respiratory: chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, patients with a history of drug allergies, asthma or hay fever, and multiple allergies where the benefit/risk of administering Definity® is considered unfavorable by the study physicians in relation to the product labeling for Definity
  23. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03322813

Layout table for location information
United States, Maryland
University of Maryland Medical System
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Graeme Woodworth, MD University of Maryland
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03322813    
Other Study ID Numbers: BT004
First Posted: October 26, 2017    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by InSightec:
Blood Brain Barrier
Blood Brain Barrier Disruption
Infiltrating glioma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue